Programmable Medicine Showcases Myeloid-Targeted JAK Inhibitors Aimed at Improving Rheumatoid Arthritis Treatment Safety at ACR 2026

Programmable Medicine Presents Preclinical Data Supporting Myeloid-Directed JAK-Dendranib Development for Rheumatoid Arthritis Programmable Medicine (PMED), a biotechnology company developing targeted nanomedicine approaches for inflammatory diseases, announced that it will present…

Read MoreProgrammable Medicine Showcases Myeloid-Targeted JAK Inhibitors Aimed at Improving Rheumatoid Arthritis Treatment Safety at ACR 2026

Xencor Presents Initial Plamotamab Data in Rheumatoid Arthritis and Updates XmAb657 Clinical Progress at ACR 2026

Xencor Reports Initial Plamotamab Phase 1b Data Showing Deep B-Cell Depletion and Preliminary Clinical Improvements in Rheumatoid Arthritis Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered antibodies for cancer and…

Read MoreXencor Presents Initial Plamotamab Data in Rheumatoid Arthritis and Updates XmAb657 Clinical Progress at ACR 2026